Physician profile
Caitlin Normoyle
NPI 1588403265
$1,794.70
in general payments reported to CMS, 2019-2025
19 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $25.92 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,794.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $364.31 | 2025 | |
| Novo Nordisk INC | $353.10 | 2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.34 | 2025 | Jardiance |
| Pfizer INC. | $112.56 | 2024-2025 | |
| Amgen INC. | $101.68 | 2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $94.55 | 2025 | Spravato |
| Ardelyx, INC. | $88.61 | 2025 | Ibsrela |
| Lilly USA, LLC | $87.96 | 2025 | Kisunla |
| Exact Sciences Corporation | $79.37 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $69.08 | 2025 | Farxiga |
| Astellas Pharma US INC | $54.48 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $42.02 | 2025 | |
| Axsome Therapeutics, INC. | $31.54 | 2025 | Auvelity |
| Currax Pharmaceuticals LLC | $27.58 | 2025 | Contrave |
| Vertex Pharmaceuticals Incorporated | $24.74 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.69 | 2025 | Xifaxan |
| Actelion Pharmaceuticals US, INC. | $18.44 | 2025 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $18.29 | 2025 | Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $16.36 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Normoyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.